Join to View Full Profile
1021 Morehead Medical DrSte ACharlotte, NC 28204
Phone+1 980-442-2000
Dr. Kim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
Baylor College of MedicineResidency, Internal Medicine, 1996 - 1999
Northwestern University The Feinberg School of MedicineClass of 1996
Certifications & Licensure
CA State Medical License 2022 - 2026
NC State Medical License 2013 - 2026
TX State Medical License 1998 - 2026
Clinical Trials
- A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Start of enrollment: 2014 Mar 28
- A Study of Regorafenib in Advanced Pancreatic Cancer Patients Start of enrollment: 2014 Jun 06
- Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006) Start of enrollment: 2015 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies.Tony Mok, Makoto Nishio, Tatsuya Yoshida, Myung-Ju Ahn, Kentarou Kudou
Lung Cancer. 2025-11-01 - Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024.Narjust Florez, Sandip Patel, Heather A Wakelee, Julia Rotow, Elaine Shum
Cancer. 2025-09-01 - 2 citationsHow to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer.Jyoti Malhotra, Edward S Kim
JCO Oncology Practice. 2024-11-01
Journal Articles
- Stress Hormones Promote EGFR Inhibitor Resistance in NSCLC: Implications for Combinations with Β-blockersHai Tran, Anil K Sood, John V Heymach, Roy Herbst, Lecia V Sequist, Edward S Kim, Science Magazine
Lectures
- Barriers to clinical trial accrual: Clinical trialists' perspectives.2019 ASCO Annual Meeting - 6/1/2019
- Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC) that progressed on alectinib ...2019 ASCO Annual Meeting - 6/1/2019
- 94th Annual Meeting of American Radium SocietyAmerican Radium Society, Las Vegas, Nevada - 4/28/2012
Authored Content
- Moving Away (Finally) from Doublet Therapy in Lung Cancer: Immunotherapy and KEYNOTE-189September 2018
Press Mentions
City of Hope Opens Only Cancer Specialty Hospital in Orange County, Calif., Advancing a National Model for Cancer Research and TreatmentNovember 19th, 2025- City of Hope Prepares to See First Patients at Cancer Only HospitalNovember 17th, 2025
- City of Hope Unveils Innovative National Clinical Trials Model to Fast-Track Cancer ResearchSeptember 9th, 2025
- Join now to see all
Grant Support
- Personalizing NSCLC Therapy: Exploiting KRAS Activated PathwaysNIH/NCI2010–2015
- U10 Full Member Application Affiliated with SWOGNIH/NCI2011–2012
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
